Home › Ligand Partner Spectrum Pharmaceuticals Receives FDA Approval Of EVOMELA (melphalan) For Injection
 

Keywords :   


Ligand Partner Spectrum Pharmaceuticals Receives FDA Approval Of EVOMELA (melphalan) For Injection

2016-03-30 07:12:27| drugdiscoveryonline Home Page

Ligand Pharmaceuticals Incorporated announces thatSpectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, received approval from the U.S. Food and Drug Administration (FDA) of EVOMELA

Tags: partner approval spectrum receives

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
16.05CFTC charges Agridime and its co-founders with a fraudulent cattle scheme
16.05Baleage: Advantageous for first cutting hay
16.05Hydrosome Labs Technology Poised to Usher in New Era of Precision Fermentation
16.05Tools for environmental challenge
16.05Hubbl integrates global streaming apps with Amdocs
16.05Croda Beauty Launches New Ceramide Range
16.05Doves New Bond Strength Range Contains Proprietary Bio-Protein Care and Peptides
16.05Mount Sinai Awarded $6.6 Million from National Institutes of Health to Investigate Treatment ...
More »